Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6411
    -0.0015 (-0.23%)
     

  • OIL

    82.30
    -0.43 (-0.52%)
     

  • GOLD

    2,395.50
    -2.50 (-0.10%)
     

  • Bitcoin AUD

    101,180.41
    +5,062.09 (+5.27%)
     

  • CMC Crypto 200

    1,333.31
    +20.68 (+1.60%)
     

  • AUD/EUR

    0.6018
    -0.0013 (-0.21%)
     

  • AUD/NZD

    1.0892
    +0.0017 (+0.15%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,838.90
    -38.15 (-0.48%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,720.42
    -116.98 (-0.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Could This Vaccine Become Sanofi's Latest Blockbuster?

Kody Kester, The Motley Fool
·3-min read
Could This Vaccine Become Sanofi's Latest Blockbuster?

Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.

Continue reading